ArticleERJ open research2020
Inhaled therapy reduces COPD mortality.
Article in ERJ open research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Efficacy, pharmacokinetics, and safety of nebulized HL231 inhalation solution in patients with chronic obstructive pulmonary disease: a randomized trial.Journal of thoracic disease · 2025Article
- Delaying disease progression in COPD with early escalation to triple therapy: a modelling study (DEPICT-2).ERJ open research · 2025Article
- ICS/Ultra LABA in the Treatment of Obstructive Airway Diseases: A Consensus of Indian Experts.Advances in respiratory medicine · 2022Article
- Inhaled corticosteroids reduce senescence in endothelial progenitor cells from patients with COPD.Thorax · 2022Article
- Prevalence and burden of COPD misclassification in the Canadian Longitudinal Study on Aging (CLSA).BMJ open respiratory research · 2022Article
- Effectiveness of Extrafine Single Inhaler Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) in Germany - The TriOptimize Study.International journal of chronic obstructive pulmonary disease · 2022Observational
- Triple Therapy in COPD: Can We Welcome the Reduction in Cardiovascular Risk and Mortality?Frontiers in medicine · 2022Review
- COPD mortality and exacerbations in the placebo group of clinical trials over two decades: a systematic review and meta-regression.ERJ open research · 2022Review
- Maximizing Adherence and Gaining New Information For Your Chronic Obstructive Pulmonary Disease (MAGNIFY COPD): Study Protocol for the Pragmatic, Cluster Randomized Trial Evaluating the Impact of Dual Bronchodilator with Add-On Sensor and Electronic Monitoring on Clinical Outcomes.Pragmatic and observational research · 2021Article
- Beyond Dual Bronchodilation - Triple Therapy, When and Why.International journal of chronic obstructive pulmonary diseaseArticle
- Overcoming Therapeutic Inertia to Reduce the Risk of COPD Exacerbations: Four Action Points for Healthcare Professionals.International journal of chronic obstructive pulmonary diseaseArticle
- A Cohort Study to Evaluate the Risk of Hospitalisation for Congestive Heart Failure Associated with the Use of Aclidinium and Other Chronic Obstructive Pulmonary Disease Medications in the UK Clinical Practice Research Datalink.International journal of chronic obstructive pulmonary diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.